Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results and Provides Business Update
March 11, 2021 16:01 ET
|
Eloxx Pharmaceuticals
We expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of this year We have expanded our global Phase 2 clinical trial beyond the U.S., Europe and...
Eloxx Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 11, 2021
March 04, 2021 17:14 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Cystic Fibrosis
February 09, 2021 07:00 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology in Drug Development
January 26, 2021 07:00 ET
|
Eloxx Pharmaceuticals
Publication titled: “A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects” WALTHAM, Mass., Jan. ...
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology
January 20, 2021 07:00 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Increased Funding and Support for ELX-02 Global Phase 2 Clinical Trial Program
January 13, 2021 09:00 ET
|
Eloxx Pharmaceuticals
The CF Foundation’s partial funding of the U.S. trial has been extended to partial funding of the global clinical trial program which includes Europe and Israel Expect to report top line data from...
Eloxx Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 18, 2020 11:30 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals Reports Third Quarter 2020 Financial and Operating Results and Provides Business Update
November 05, 2020 16:01 ET
|
Eloxx Pharmaceuticals
Expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of 2021 The independent Safety Review Committees for our Phase 2 cystic fibrosis clinical trial...
Eloxx Announces The Publication of Two Manuscripts on ELX-02 and It’s ERSG Library In Two Leading Journals
October 27, 2020 07:30 ET
|
Eloxx Pharmaceuticals
A Publication titled: “ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease” has been published in the Expert Opinion on Investigational Drugs...
Eloxx Presents Two Preclinical Posters at the 2020 North American Cystic Fibrosis Virtual Conference
October 22, 2020 08:57 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...